OncoMatch/Sarcoma/CDK4 amplification (liposarcoma)

SarcomaCDK4 amplification (liposarcoma) Clinical Trials

CDK4 amplification — co-occurring with MDM2 amplification on 12q13-15 — defines well-differentiated and dedifferentiated liposarcoma, among the most common sarcoma subtypes. CDK4/6 inhibitors are not a standard approved therapy in sarcoma; agents such as palbociclib and abemaciclib have shown modest activity in CDK4-amplified sarcoma in early trials. Trials investigate CDK4/6 inhibitor combinations with MDM2 antagonists (milademetan, siremadlin), novel CDK4-selective agents, and immunotherapy for dedifferentiated liposarcoma.